Skip to content
Tenfell
Awarded contract
Published 25 Mar 2020

NHS Framework Agreement - North of England - Tranche B

NHS England · London

Key facts

Awarded
13 Feb 2020
Contract starts
01 Mar 2020
Contract ends
28 Feb 2022
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 35 suppliers

SupplierValue
Takeda UK Limited—
Janssen-Cilag Ltd—
Merck Sharp & Dohme UK Ltd—
Pfizer Ltd—
Teva UK Ltd—
BAYER PUBLIC LIMITED COMPANY—
Amgen Ltd—
Sandoz Ltd—
Typharm Ltd—
Biogen—
Celltrion Healthcare United Kingdom Limited—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Gilead Sciences Limited—
Ipsen—
Merck Serono Limited—
Mylan—
Novartis Pharmaceuticals UK Ltd—
Novo Nordisk—
Roche Products Ltd—
UCB Pharma Ltd—
Ferring Pharmaceuticals Limited—
Bristol-Myers Squibb Pharmaceuticals Ltd—
ROVI Biotech Ltd—
Techdow Pharma England Ltd—
Astellas Pharma Ltd—
Pharmasure—
Theramex HQ UK—
Daiichi Sankyo UK Ltd—
Profile Pharma Ltd—
Acre Pharma Limited—
ASPEN PHARMA LTD—
DR. REDDY'S LABORATORIES (EU) LIMITED—
NAPP LABORATORIES LIMITED—
SANOFI-AVENTIS UK HOLDINGS LIMITED—

Description

NHS Framework for the NHS North of England Region, Branded Medicines - Tranche B, Cytokine Modulators and other monoclonal Antibodies, and Fondaparinux

Offer reference number: CM/PHR/16/5527

CM/PHR/16/5527/01: NHS Framework for the NHS North Of England Region, Branded Medicines, Tranche B, 1 March 2020 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/16/5527/02: NHS Framework for the NHS North Of England Region, Branded Medicines Annual Tranche, Cytokine Modulators and other monoclonal antibodies, 1 March 2020 to 28 February 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/16/5527/03: NHS Framework agreement for Fondaparinux London, 1 March 2020 to 31 August 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. South of England, 1 March 2020 to 31 August 2020 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Midlands and East, 1 March 2020 to 28 February 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.